N-Acetylcysteine Suppresses Retinal Detachment in an Experimental Model of Proliferative Vitreoretinopathy

Campochiaro, 1997, Pathogenic mechanisms in proliferative vitreoretinopathy, Arch Ophthalmol, 115, 237, 10.1001/archopht.1997.01100150239014 Glaser, 1987, Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction, Ophthalmology, 94, 327, 10.1016/S0161-6420(87)33443-8 Charteris, 1998, Growth factors in proliferative vitreoretinopathy, Br J Ophthalmol, 82, 106, 10.1136/bjo.82.2.106 Laqua, 1975, Glial cell proliferation in retinal detachment (massive periretinal proliferation), Am J Ophthalmol, 80, 602, 10.1016/0002-9394(75)90390-6 Ryan, 1993, Traction retinal detachment. XLIX Edward Jackson Memorial Lecture, Am J Ophthalmol, 115, 1, 10.1016/S0002-9394(14)73518-4 Blumenkranz, 1982, Fluorouracil for the treatment of massive periretinal proliferation, Am J Ophthalmol, 94, 458, 10.1016/0002-9394(82)90239-2 Wiedemann, 1987, Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy, Am J Ophthalmol, 104, 10, 10.1016/0002-9394(87)90286-8 Wiedemann, 1985, Daunomycin in the treatment of experimental proliferative vitreoretinopathy: effective doses in vitro and in vivo, Invest Ophthalmol Vis Sci, 26, 719 Wu, 2008, Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells, J Ocul Pharmacol Ther, 24, 25, 10.1089/jop.2007.0044 Falkenstein, 2008, Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186, Curr Eye Res, 33, 599, 10.1080/02713680802226582 Kim, 2002, Mechanisms in proliferative vitreoretinopathy, Ophthalmol Clin North Am, 15, 81, 10.1016/S0896-1549(01)00008-6 Murata, 1997, Ocular gene therapy: experimental studies and clinical possibilities, Ophthalmic Res, 29, 242, 10.1159/000268022 Chang, 2008, Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy, Am J Ophthalmol, 146, 440, 10.1016/j.ajo.2008.05.002 Menon, 2009, New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy, Eye, 23 Suppl 1, S1, 10.1038/eye.2009.13 Hochhaus, 2004, Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), Ann Hematol, 83 Suppl 1, S65 Lei, 2007, A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy, Invest Ophthalmol Vis Sci, 48, 2335, 10.1167/iovs.06-0965 Cui, 2009, PDGF receptors are activated in human epiretinal membranes, Exp Eye Res, 88, 438, 10.1016/j.exer.2008.10.020 Andrews, 1999, Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy, Invest Ophthalmol Vis Sci, 40, 2683 Ikuno, 2000, Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor, Invest Ophthalmol Vis Sci, 41, 3107 Ikuno, 2002, An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor, Invest Ophthalmol Vis Sci, 43, 2406 Lei, 2009, Growth factors outside of the PDGF family employ ROS/SFKs to activate PDGF receptor alpha and thereby promote proliferation and survival of cells, J Biol Chem, 284, 6329, 10.1074/jbc.M808426200 Rosenkranz, 1999, Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis, J Biol Chem, 274, 28335, 10.1074/jbc.274.40.28335 Nakagawa, 1995, Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy, Invest Ophthalmol Vis Sci, 36, 2388 Wong, 2002, Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells, Can J Ophthalmol, 37, 211, 10.1016/S0008-4182(02)80112-0 Gelderloos, 1998, A role for Src in signal relay by the platelet-derived growth factor alpha receptor, J Biol Chem, 273, 5908, 10.1074/jbc.273.10.5908 Maberley, 2006, Vitreous leptin levels in retinal disease, Eye, 20, 801, 10.1038/sj.eye.6702011 Heeneman, 2000, Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor: key role for the p66 adaptor protein Shc, J Biol Chem, 275, 15926, 10.1074/jbc.M909616199 Sundaresan, 1995, Requirement for generation of H2O2 for platelet-derived growth factor signal transduction, Science, 270, 296, 10.1126/science.270.5234.296 He, 2008, Connective tissue growth factor as a mediator of intraocular fibrosis, Invest Ophthalmol Vis Sci, 49, 4078, 10.1167/iovs.07-1302 Abu El-Asrar, 2007, Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders, Int Ophthalmol, 27, 11, 10.1007/s10792-007-9053-x Fastenberg, 1982, A comparison of different cellular inocula in an experimental model of massive periretinal proliferation, Am J Ophthalmol, 93, 559, 10.1016/S0002-9394(14)77369-6